151 search results for: Pathophysiology
World Anosmia Awareness Day
Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.
FeNO as a Biomarker for Type 2 Asthma
Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.
IgE as a Biomarker for Type 2 Asthma
Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.
Eosinophils as a Biomarker for Type 2 Asthma
Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.
From Protective Type 2 Immunity to Aberrant Type 2 Inflammation
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 immunity evolved to protect against parasites, venoms, and toxins, and how its dysregulation can result in aberrant type 2 inflammation underlying multiple chronic inflammatory diseases.
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation
Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
Engage with experts Klaus Rabe, Stephanie Christenson, and Paola Rogliani in an educational symposium to explore the inflammatory pathways and phenotypes of COPD, investigate the genetic associations of IL-33 and COPD, examine early preclinical findings, and review ongoing research on the role of IL-33 in COPD.
